GeoVax (GOVX) $0.15 And Nope, We Are Not Panicking!
Full Report Monday!
And we're not letting this spoil our Christmas..
LIVE QUOTE
But yes, it sucks, and yes, we've been here before. And no, we were...
Inbcubator Society Pass (SOPA), Expanding into Private AI Software Companies, and Private AI Data...
Society Pass was riding high earlier this year, after announcing they had successfully spun off one of its holding companies NusaTrip (NUTR), into a...
GeoVax (GOVX) Reports Both Favorable Safety and “It’s Working” News for its Cancer...
Official Headline is "GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck...
Noble’s “Wall Street South” Conference Schedule.
To make the conference most enjoyable and productive, quickly scan over each company in the eBook below. Then print out and circle their name...
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
BioPharm
David Dodd, GeoVax Labs (NASDAQ: GOVX), opines on why vaccine platform diversity is critical in the United States.
Editor's Note: The views an opinions expressed...
Sekur Private Data’s (SWISF) Fortress Grade Security Getting Noticed. Huge Wall Street Conference Next...
Noble's "Wall Street South" Conference Next Tuesday In Boca Raton.
Sekur Private Data's (SWISF) Fortress Grade Security Getting Noticed.
If a picture is worth a thousand...
Nasdaq Considers Stricter Delisting Rules for Stocks Under One Dollar.
Oh Boy, This Can Be Looked as Impending Diasters or Impending Opportunities. We Think Opportunities.
For the record, delisting companies soley on the basis of...
AI is Life Changing. Not Sometime in the Future, but Today.
AI Creates More Time For Sunday Bloody Mary's!
OMG, AI (we are using Copilot) is truly life-changing.
We believe AI will lead to 20% unemployment by 2030....
China and the US Fighting a Battle for Biotech Dominance
An Expert from GeoVax (GOVX) Discusses how China may be Poised to Overtake the US as the World Leader in the Industry.
MBGA
John Crowley,...
Happy News! GSK (GSK) Just Paid $367 Million, for Synvidia’s Pre-Clinical Trial Cancer Treatment.
One of the Fun Features of Biotech Investing, is Getting Paid on a Treatment That Hasn't Even Entered Clinical Trials.
A lot of investors...
Latest article
Fusion Energy Starter.
VC-Funded Fusion Energy Companies
"The fastest way to deploy fusion and I believe one of my forecasts is we will replace every coal and natural...
Party Time at UniQure (QURE)! From $8.86 to $47.21, up 432%.
I. No Bells, No Baskets. UniQure (QURE) $47 up Huge. Still Not Out Of The Woods!
II. Replimune (REPL) $11.23. Gains 28% in Sympathy with...
We’re Up 360% in Six Weeks. Replimune (REPL).
That's a Gain of $604 Million, and That Ain't Bad!
Six brokerage firms downgraded Replimune (REPL), around the same time we added it to...
